Adjuvance Technologies Announces NIH Funding for COVID-19 Vaccine Research

This week, Adjuvance Technologies Inc., a member of Bio Nebraska, announced that they have been awarded supplemental contract funding from the National Institute of Allergy and Infectious Diseases (NIAID). The funds will be used to evaluate TQL1055, manufactured by Adjuvance, with SARS-CoV2 antigen, manufactured by NIH (The National Institutes of Health). You can read the full announcement on their website.

Read the announcement on their website here.